ClinicalTrials.gg
Active, not recruitingNCT06245408Updated Jan 8, 2026

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

A Phase 3 interventional study of Dazodalibep and Placebo in Sjögren's Syndrome (SS), sponsored by Amgen. Active, not recruiting at 194 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
434
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.

Enrollment
9th of 76
434 · median 57
Started
2024
with 8 others
Phase 3
12 of 111
3 open now
Primary completion
2026-10
later than 3 of 27 live
Registered
91st of 111
by date
Lead sponsor
7 of 111
Amgen

Among the 111 studies in Sjogren's Syndrome with a site in United States, this one is the 9th largest by enrollment of the 76 interventional ones that give a count, is one of 9 that started in 2024, is one of 12 in phase 3, reaches primary completion later than 3 of the 27 other live ones, and was the 91st registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Sjogren's Syndrome with a site in United States, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state

Secondary Objectives:

  1. To evaluate the effect of dazodalibep on patient-reported outcomes (PROs) in participants with SS.
  2. To evaluate the effect of dazodalibep on measures of systemic activity, PROs, and salivary flow in participants with SS
  3. To evaluate the safety and tolerability of multiple doses of dazodalibep in participants with SS
Read the detailed description

Acquired from Horizon in 2024.

03

Conditions studied

  • Sjögren's Syndrome (SS)

Browse trials for

Keywords

  • European Alliance of Associations for Rheumatology Sjögren's Syndrome Disease Activity Index (ESSDAI)
  • European Alliance of Associations for Rheumatology Sjögren's Syndrome Patient Reported Index (ESSPRI)
  • European Alliance of Associations for Rheumatology (EULAR)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Diagnosed with SS by meeting the 2016 ACR/EULAR Classification Criteria
  2. Have an ESSPRI score of ≥ 5 at screening.
  3. Have an ESSDAI score of \< 5 at screening.
  4. Positive for either anti-Ro autoantibodies or RF, or both at screening (as per the definition of the standard central laboratory test).
  5. Residual salivary gland function as defined by whole stimulated salivary flow > 0.1 mL/min.
  6. Vaccinated against SARS-CoV-2 according to current local authority guidelines at least 2 weeks prior to screening unless participant refuses vaccination.
  7. Meets all of the following tuberculosis (TB) criteria:

    1. No history of latent or active TB prior to screening, except for latent TB with documented completion of locally appropriate treatment.
    2. No signs or symptoms suggestive of active TB from medical history or physical examination.
    3. No recent (≤ 12 weeks of screening) close contact with a person with active TB (close contact is defined as ≥ 4 hours/week OR living in the same household OR in a house where a person with active TB is a frequent visitor).
    4. Negative Interferon Gamma Release Assay (IGRA) test result for TB at screen unless previously treated as per Inclusion Criterion. Participants with an indeterminate test result can repeat the test, but if the repeat test is also indeterminate, they are excluded.
    5. A chest radiograph (obtained during the screening period or any time within 12 weeks prior to screening) with no evidence of current active TB or other infection, or prior TB, , or abnormalities suggesting an active process (unless due to SS).

Key Exclusion Criteria:

  1. Individuals with medical history of confirmed deep venous thrombosis, pulmonary embolism, or arterial thromboembolism within 2 years of screening.
  2. History or presence of concomitant polymyositis or dermatomyositis or systemic sclerosis.
  3. Active malignancy or history of malignancy within the last 5 years, except as follows:

    1. In situ carcinoma of the cervix treated with apparent success with curative therapy > 12 months prior to screening; OR
    2. Cutaneous basal cell carcinoma following presumed curative therapy.
  4. Individuals who are pregnant or lactating or planning to become pregnant during the study.
  5. Individuals with known history of severe allergy or reaction to any component of the IP formulation or to any other biologic therapy.
  6. Individuals with any severe cardiovascular, respiratory, endocrine, gastrointestinal, hematological, neurological, psychiatric, or systemic disorder or any other condition that, in the opinion of the Investigator, would place the individual at unacceptable risk of complications, interfere with evaluation of the IP, or confound the interpretation of participant safety or study results.
  7. Individuals who have a positive test for, or have been treated for, , or infection.
  8. Individuals with a positive test for SARS-CoV-2 on the day of randomization or symptoms suggestive of SARS-CoV-2 at randomization or significant exposure to coronavirus disease 2019 (COVID-19) within 10 calendar days prior to randomization.
  9. Individuals with:

    1. A history of more than one episode of herpes zoster and/or opportunistic infections in the last 12 months, with the exception of non-invasive herpes simplex at any site, oral candidiasis, vaginal candidiasis, or cutaneous fungal infections, which are permitted within the prior 12 months unless of unusual severity.
    2. Active infection requiring systemic treatment at the time of screening or through randomization, or history of more than 2 infections requiring IV antibiotics within 12 months prior to screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
434 participants (actual)

Study arms

  • Experimental
    Dazodalibep Dose 1

    Participants will be administered dose 1 of dazodalibep by intravenous (IV) infusion.

    Drug: Dazodalibep

  • Experimental
    Dazodalibep Dose 2

    Participants will be administered dose 2 of dazodalibep by IV infusion.

    Drug: Dazodalibep

  • Placebo comparator
    Placebo

    Participants will be administered placebo by IV infusion.

    Drug: Placebo

Interventions

  • IV infusion

    Also known as: VIB 4920, MEDI4920

  • DrugPlacebo

    IV infusion

06

What researchers measure

Primary outcomes

  1. Change from baseline in ESSPRI score

    Time frame: At Week 48

  2. Change from baseline in Diary for Assessing Sjogren's Patient Reported Index (DASPRI ) score

    Time frame: At week 48

Secondary outcomes

  1. Proportion of participants achieving meaningful improvement in DASPRI

    Time frame: At Week 48

  2. Proportion of participants achieving ESSPRI [1.5] response

    Time frame: At Week 48

  3. Change from baseline in Patient-Reported Outcomes Measurement Information System Fatigue-Short Form 10a (PROMIS-Fatigue SF-10a)

    Time frame: At Week 48

  4. Change from baseline in DASPRI Dryness

    Time frame: At Week 48

  5. Change from baseline in ESSPRI Dryness

    Time frame: At Week 48

  6. Change from baseline in DASPRI Pain

    Time frame: At Week 48

  7. Change from baseline in ESSPRI Pain

    Time frame: At Week 48

  8. Change from baseline in 36-item Short Form Survey (SF-36) Physical Component Summary (PCS) score

    Time frame: At Week 48

  9. Change from baseline in DASPRI total score

    Time frame: At week 12 and week 24

  10. Change from baseline in ESSPRI total score

    Time frame: At week 12, Week 24

  11. Change from baseline in DASPRI Fatigue

    Time frame: At Week 48

  12. Change from baseline in ESSPRI fatigue domain score

    Time frame: At Week 48

  13. Change from baseline in total stimulated salivary flow

    Time frame: At Week 48

  14. Number of participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: Baseline (Day 1) to Week 56

  15. Number of participants With Treatment Emergent Serious Adverse Events (TESAEs)

    Time frame: Baseline (Day 1) to Week 56

  16. Number of participants With Adverse Events of Special Interest (AESIs)

    Time frame: Baseline (Day 1) to Week 56

07

Study locations

194 sites

Showing the first 100 of 194 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Oct 2026, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2024
First posted
Feb 7, 2024
StartActual
Apr 8, 2024
Primary completionEst.
Oct 22, 2026
CompletionEst.
Dec 17, 2026
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06245408
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 7, 2024
Start date
Apr 8, 2024
Primary completion
Oct 22, 2026 (estimated)
Completion
Dec 17, 2026 (estimated)
Last update
Jan 8, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dazodalibep

Start the discussion